North America Inhalation Devices Market Outlook, 2031
The North America Inhalation Devices Market is segmented into By Product Type (Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), Soft Mist Inhalers (SMIs), Nebulizers); By Therapeutic Application (Asthma, COPD, Others); By End User (Hospitals & Respiratory Care Centers, Home Care Settings, Clinics & Ambulatory Care); By Distribution Channel (Institutional/ Hospital Pharmacies, Retail Pharmacies, Online Pharmacies); By Technology (Manual, Digital/Smart).
- Bonafide Research
- 13-10-2026
- Pages : 95
- Figures : 6
- Tables : 16
- Region : North America
- Category : Lifescience & Healthcare
- Medical Devices
- Schedule a Call
-
Sikandar Kesari — Research Analyst
The North America Inhalation Devices Market was valued at more than 15.92 Billion in 2025, driven by increasing cases of respiratory illnesses.
- Historical Period2020-2024
- Base Year2025
- Forecast Period2026-2031
- Market Size (2025) USD 15.92 Billion
- Largest MarketUnited States
- Fastest Market Mexico
- Format
Featured Companies
- 1. Koninklijke Philips N.V.
- 2. Lupin Limited
- 3. Novartis International AG
- 4. Viatris Inc.
- 5. Boehringer Ingelheim
- 6. AstraZeneca plc
- More...
Inhalation Devices Market Analysis
The North America inhalation devices market comprises medical systems such as pressurized metered-dose inhalers (pMDIs), dry-powder inhalers (DPIs), soft-mist inhalers, and nebulizers designed to deliver targeted pharmaceutical therapies directly into the respiratory tract. Holding the largest global market share, this region is vital due to its role in managing chronic, high-burden conditions like asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. Market expansion is primarily driven by the rising prevalence of respiratory illnesses, worsening air quality from urban pollution and wildfire smoke, an aging demographic, and strong reimbursement coverage. Its high importance stems from improving drug bioavailability, enabling rapid onset of relief, minimizing systemic side effects, and supporting a shift toward home-based care. Key industry associations, such as the American Thoracic Society (ATS), the American Lung Association (ALA), and the Asthma and Allergy Foundation of America (AAFA), play pivotal roles in this ecosystem. These organizations engage in multi-faceted activities, including driving clinical research, publishing evidence-based treatment guidelines, advocating for clean air legislation, educating patients on proper inhaler technique, and lobbying for expanded access to digital and eco-friendly respiratory therapies. Furthermore, integration with regulatory bodies like the U.S. FDA ensures rigorous device efficacy, safety standards, and the adoption of low-global-warming-potential propellants. Ongoing innovation particularly smart inhalers equipped with bluetooth sensors for real-time adherence tracking continues to elevate patient outcomes and solidifies North America's leadership in modern pulmonary care. According to the research report, "North America Inhalation Devices Market Outlook, 2031," published by Bonafide Research, the North America Inhalation Devices Market was valued at more than 15.92 Billion in 2025. Dominant pharmaceutical and medical technology leaders driving this space include GlaxoSmithKline (GSK), AstraZeneca, Boehringer Ingelheim, Teva Pharmaceutical Industries, Viatris, Philips Healthcare, and OMRON Corporation. Significant growth opportunities lie in the adoption of digital health, connected smart inhalers with integrated sensors, expanded home-care tele-health models, and non-CFC eco-friendly low-GWP propellants. Key company developments highlight this shift toward digital integration and environmental compliance: AstraZeneca and GSK continue expanding connected respiratory platforms, Teva leads advancements in digital inhalers with integrated sensors, and ResMed recently restructured its portfolio to focus heavily on connected home respiratory care. From a supply chain perspective, the regional market operates through a multi-tiered structure involving specialized contract development and manufacturing organizations (CDMOs) like Aptar Pharma and H&T Presspart for micro-molded actuators, valves, and dose counters, alongside active pharmaceutical ingredient (API) suppliers. Major pharmaceutical firms assemble and fill these drug-device combination products under strict U.S. FDA current Good Manufacturing Practice (cGMP) regulations before distributing them through consolidated pharmaceutical wholesalers (e.g., McKesson, AmerisourceBergen, Cardinal Health) to retail pharmacies, hospital networks, and direct-to-patient homecare channels. While raw material supply fluctuations, complex cold-chain/sterile logistics, and stringent FDA approval cycles present potential bottlenecks, rising prevalence of asthma and COPD across American demographics continues to solidify market expansion.
to Download this information in a PDF
What's Inside a Bonafide Research`s industry report?
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Dynamics
Market Drivers
• Rising burden of chronic respiratory diseases and environmental triggers: The primary factor propelling the North American inhalation devices market is the surging prevalence of chronic respiratory illnesses, particularly Asthma, Chronic Obstructive Pulmonary Disease (COPD), and cystic fibrosis. In the United States and Canada, millions of patients depend on maintenance and rescue inhalation therapies as primary medical interventions. This growing disease burden is further exacerbated by deteriorating environmental conditions such as seasonal wildfire smoke across western regions, urban air pollution, and changing allergen seasons.• Aging demographics and the shift toward home-based care: North America is experiencing a rapid growth in its geriatric population, a demographic that disproportionately suffers from progressive pulmonary conditions. Simultaneously, the healthcare ecosystem is undergoing a structural shift toward decentralized and home-based patient care to curb hospital readmission rates and reduce overall clinical costs. Modern, user-friendly inhalation devices such as portable, battery-operated nebulizers and breath-actuated dry-powder inhalers allow elderly and chronically ill patients to manage their respiratory regimens independently at home.
Market Challenges
• High device costs and onerous coverage reimbursement hurdles: Despite strong demand, the premium pricing of next-generation inhalation technologies presents a major restraint. Advanced breath-actuated inhalers, soft-mist systems, and sensor-enabled smart devices involve high research, development, and manufacturing costs. Commercial insurers and public payers often place these novel combination products into higher cost-sharing tiers, forcing patients to pay high out-of-pocket expenses or opt for older, less efficient generic inhalers.• Complex FDA regulatory frameworks and strict cGMP requirements: Inhalation devices are classified as complex drug-device combination products, making them subject to rigorous oversight by the U.S. Food and Drug Administration (FDA) and Health Canada. Manufacturers must demonstrate not only drug efficacy and device safety, but also precise dose consistency, drug-container compatibility, and device human-factors engineering. Navigating bioequivalence guidelines for generic inhalers is notoriously difficult, leading to extended development timelines, costly clinical bridging trials, and delayed product launches. Regulatory friction and the risk of device recalls slow down product innovation cycles.
Market Trends
• Transition to eco-friendly, low-GWP propellants: A major transformational trend across North America is the industry-wide mandate to phase out traditional hydrofluoroalkane (HFA-134a and HFA-227ea) propellants in pressurized metered-dose inhalers (pMDIs) due to their high global warming potential (GWP). Leading pharmaceutical manufacturers are investing heavily in reformulating pMDI portfolios with next-generation, low-GWP propellants like HFA-152a and HFO-1234ze. Driven by regulatory environmental standards and corporate sustainability goals, this green transition is reshaping the supply chain, triggering plant retrofits, new clinical trials, and portfolio revamps across the region.• Integration of smart connected technologies and digital therapeutics: The convergence of digital health and respiratory care has spurred the adoption of connected smart inhalers. Modern inhalers are increasingly built with or retrofitted with Bluetooth sensors, electronic dose counters, and mobile app connectivity that monitor inhalation technique, track daily dosage adherence, and log environmental conditions in real time. These platforms transmit actionable patient data directly to clinicians, supporting remote patient monitoring (RPM) and telehealth workflows.
Inhalation Devices Segmentation
| By Product Type | Metered Dose Inhalers (MDIs) | |
| Dry Powder Inhalers (DPIs) | ||
| Soft Mist Inhalers (SMIs) | ||
| Nebulizers | ||
| By Therapeutic Application | Asthma | |
| COPD | ||
| Others | ||
| By End User | Hospitals & Respiratory Care Centers | |
| Home Care Settings | ||
| Clinics & Ambulatory Care | ||
| By Distribution Channel | Institutional/ Hospital Pharmacies | |
| Retail Pharmacies | ||
| Online Pharmacies | ||
| By Technology | Manual | |
| Digital/Smart | ||
| North America | United States | |
| Canada | ||
| Mexico | ||
Dry powder inhalers are the leading product type because they provide a portable, propellant-free method of delivering maintenance medications for asthma and chronic obstructive pulmonary disease (COPD), supported by established clinical use and a broad range of approved inhaler products. Dry powder inhalers have an important place in North America's respiratory care landscape because their design combines medication delivery with practical advantages for patients who need treatment over extended periods. Unlike pressurized metered-dose inhalers, which release medication using a propellant, DPIs generally disperse powdered medicine through the patient's inhalation effort. This design eliminates the need for a propellant and removes the requirement to coordinate pressing a canister with breathing in, although patients must still generate sufficient inspiratory flow to use the specific device correctly. The National Heart, Lung, and Blood Institute explains that DPIs contain premeasured doses and are used for asthma, COPD, and other chronic lung diseases, illustrating their relevance to long-term respiratory management. Their role is reinforced by the availability of different device designs, including single-dose and multidose systems, which allow manufacturers to pair inhaler technology with particular medicines and treatment schedules. In routine care, patients may use inhaled corticosteroids to control airway inflammation, long-acting bronchodilators to support breathing, or combinations of these medicines when clinically appropriate. A compact device can also be carried to work, school, or during travel, helping patients incorporate prescribed therapy into everyday activities. However, DPIs are not universally suitable: people experiencing severe breathing difficulty or those unable to inhale forcefully enough may require another delivery method, and individual product instructions must be followed carefully. The US Food and Drug Administration maintains specific quality guidance for inhalation powders, reflecting the technical requirements involved in manufacturing reliable products and ensuring consistent drug delivery. Asthma is the leading therapeutic application because it affects millions of people across North America and frequently requires repeated inhaled treatment to control airway inflammation, relieve symptoms, and reduce the risk of exacerbations. Asthma has a substantial and continuing influence on inhalation device demand because it is a chronic airway condition that can affect children, working-age adults, and older people, requiring treatment plans that accommodate different levels of disease severity and changing symptoms. In the United States, the Centers for Disease Control and Prevention reported that approximately 27.8 million people had current asthma in 2023, including about 4.8 million children and 23.0 million adults. The same dataset recorded asthma attacks during the preceding year among 42.3% of people with current asthma, demonstrating why effective medication delivery remains an important component of disease management. In Canada, the Public Health Agency of Canada has also identified asthma as a significant chronic condition affecting more than three million people, further establishing its relevance across the region. Inhalation devices are central to asthma treatment because they deliver medicines directly into the respiratory tract, allowing clinicians to prescribe inhaled corticosteroids for inflammation control and bronchodilators for symptom relief according to the patient's needs. Treatment may involve a daily controller inhaler, a prescribed reliever, or a combination inhaler, depending on the patient's age, symptoms, risk profile, and clinical guidance. Asthma management also extends beyond prescriptions: patients must understand when and how to use their devices, recognize worsening symptoms, and follow an appropriate action plan. Different devices accommodate different patient capabilities, including the needs of children and people who have difficulty coordinating inhalation with device activation. Nevertheless, correct technique remains essential, and the most appropriate inhaler depends on the patient's inspiratory ability, preferences, and prescribed medication. Hospitals and respiratory care centers are the leading end-user segment because they manage acute respiratory episodes, administer supervised inhalation treatments, and provide specialized assessment and monitoring for patients with complex pulmonary conditions. Hospitals and respiratory care centers occupy a central position in the use of inhalation devices because they serve patients across a wide range of clinical circumstances, from sudden breathing difficulties to complicated chronic respiratory disease. Emergency departments regularly evaluate people experiencing severe asthma attacks, COPD exacerbations, and other conditions that may impair normal breathing. Depending on the diagnosis and clinical condition, healthcare professionals may administer inhaled bronchodilators through nebulizers or other suitable delivery systems, while monitoring oxygen levels, respiratory effort, and the patient's response to treatment. The Agency for Healthcare Research and Quality has documented the substantial burden associated with asthma-related emergency department visits in the United States, demonstrating the importance of acute respiratory services within the healthcare system. Inpatient departments also use inhalation equipment when patients need respiratory medication as part of a broader treatment plan. Respiratory therapists and other trained healthcare professionals can assess breathing patterns, select appropriate delivery equipment, explain correct inhalation techniques, and evaluate whether a patient is responding adequately. These responsibilities are especially important for children, older adults, critically ill patients, and individuals who cannot reliably operate a handheld inhaler during an acute episode. Hospitals also provide opportunities for supervised nebulization, equipment cleaning, infection prevention, and staff training, all of which influence device selection and handling. Respiratory care centers and pulmonary clinics contribute through lung-function assessments, treatment reviews, patient education, and follow-up for chronic conditions. In addition, institutional purchasing processes allow healthcare organizations to establish equipment standards, maintain supplies, and select devices compatible with their clinical protocols. However, hospitals do not necessarily dominate every inhalation-device category, since many patients obtain maintenance inhalers through outpatient prescriptions and manage their conditions at home. Their importance as an end-user segment instead arises from the concentration of medically complex cases, emergency interventions, professional supervision, and specialized respiratory services delivered within clinical facilities. Retail pharmacies are the leading distribution channel because they provide accessible prescription dispensing, routine inhaler refills, medication counseling, and convenient connections between respiratory patients and their ongoing treatment. Retail pharmacies play a practical role in North America's inhalation device supply chain because patients with asthma and COPD frequently need continuing access to prescribed medicines rather than a single purchase associated with diagnosis or hospitalization. Once a clinician prescribes an inhaler, patients can obtain the product through community pharmacies, where pharmacists and pharmacy staff help process prescriptions, check dispensing requirements, explain administration instructions, and address questions about refills. The United States has an extensive community pharmacy network, and published research on inhaler education describes how convenient opening hours and medication counseling make pharmacies useful locations for supporting patients with inhaled treatments. This accessibility matters because maintenance treatment can involve regular replacement of inhalers, while reliever medicines may need replenishment according to the prescribed regimen and actual use. Pharmacists can also help patients understand differences between controller and reliever medicines, follow device-specific instructions, and identify situations in which consultation with the prescribing clinician is appropriate. Evidence from a randomized study involving patients with asthma or COPD found that physical demonstration improved metered-dose inhaler technique more effectively than written and verbal information alone, highlighting the value of practical instruction during medication-related encounters. Pharmacy access also connects with insurance arrangements and prescription networks. For example, Medicare Part D plans may distinguish between in-network and out-of-network pharmacies, and some offer preferred pharmacy arrangements or mail-order supplies for eligible medicines. These arrangements illustrate how dispensing networks influence where patients obtain prescribed treatments. Retail pharmacies further benefit from their integration with routine community healthcare, allowing many patients to collect medication near home or work without attending a hospital. Manually operated inhalation devices are the leading category because conventional inhalers and nebulizers can deliver prescribed respiratory medicines without depending on connected software, digital monitoring systems, or electronic control features. Manually operated inhalation devices remain important in respiratory care because their primary function is to deliver medication through a relatively straightforward mechanical process, without requiring patients or healthcare providers to manage a digital platform. This category can include conventional pressurized metered-dose inhalers, dry powder inhalers, and manually operated nebulizer systems, although their mechanisms of drug delivery differ considerably. A metered-dose inhaler releases a measured quantity of medication when activated, whereas a dry powder inhaler uses the patient's inspiratory effort to disperse the medicine. A conventional nebulizer converts liquid medication into an inhalable aerosol using its operating mechanism, which may involve electrical power even though medication delivery is not necessarily digitally controlled. This distinction matters because manual operation does not always mean that a device requires no electricity. The practical appeal of conventional inhalers lies in their established role in treating asthma and COPD, their portability in many designs, and their compatibility with widely prescribed respiratory medicines. Patients can use suitable devices at home, during travel, or at work, provided they understand the correct technique and follow their prescription. Healthcare professionals can teach patients how to prepare a dose, inhale appropriately, clean reusable components when required, and recognize when a device needs replacement. Unlike connected inhalers, conventional devices generally do not require wireless pairing, app installation, electronic adherence tracking, or battery-powered monitoring features. This can reduce technological complexity for patients who prefer simple equipment or have limited access to smartphones and digital support.
to Download this information in a PDF
Inhalation Devices Market Regional Insights
The United States is the leading regional market because its large population, substantial burden of chronic respiratory disease, extensive healthcare infrastructure, and established pharmaceutical distribution network support widespread use of inhalation devices. The United States holds a prominent position in North America's inhalation devices market because respiratory treatment is supported by a broad network of hospitals, outpatient clinics, pharmacies, specialist practices, and home-care services serving a large and diverse population. Asthma alone creates a considerable ongoing need for inhaled medication: the CDC estimated that approximately 27.8 million Americans had current asthma in 2023, including both children and adults. COPD adds another important source of demand, particularly among older adults and people with a history of tobacco exposure or other relevant risk factors. The American Lung Association's published state-level COPD data document the condition across the country, demonstrating that respiratory care needs extend across multiple states and communities rather than being concentrated in a single locality. The country's healthcare infrastructure supports inhalation treatment through emergency services for acute breathing difficulties, specialist care for complex pulmonary disease, and outpatient prescribing for ongoing symptom management. Retail pharmacies and prescription-benefit networks provide established routes for patients to obtain inhaled medicines, while hospitals and respiratory care teams use inhalation equipment in supervised clinical settings. The United States also has a substantial pharmaceutical industry and a formal regulatory framework for inhaled drug products. The Food and Drug Administration publishes guidance addressing quality considerations for metered-dose inhalers and dry powder inhalers, reflecting the technical and regulatory requirements involved in developing these products.
to Download this information in a PDF
Companies Mentioned
- Koninklijke Philips N.V.
- Lupin Limited
- Novartis International AG
- Viatris Inc.
- Boehringer Ingelheim
- AstraZeneca plc
- Cipla Health Ltd.
- PARI Respiratory Equipment, Inc.
- Omron Corporation
- GlaxoSmithKline (GSK) plc
- Teva Respiratory LLC
- CHIESI Farmaceutici S.p.A.
Table of Contents
- 1. Executive Summary
- 2. Market Dynamics
- 2.1. Market Drivers & Opportunities
- 2.2. Market Restraints & Challenges
- 2.3. Market Trends
- 2.4. Supply chain Analysis
- 2.5. Policy & Regulatory Framework
- 2.6. Industry Experts Views
- 3. Research Methodology
- 3.1. Secondary Research
- 3.2. Primary Data Collection
- 3.3. Market Formation & Validation
- 3.4. Report Writing, Quality Check & Delivery
- 4. Market Structure
- 4.1. Market Considerate
- 4.2. Assumptions
- 4.3. Limitations
- 4.4. Abbreviations
- 4.5. Sources
- 4.6. Definitions
- 5. Economic /Demographic Snapshot
- 6. North America Inhalation Devices Market Outlook
- 6.1. Market Size By Value
- 6.2. Market Share By Country
- 6.3. Market Size and Forecast, By Product Type
- 6.4. Market Size and Forecast, By Therapeutic Application
- 6.5. Market Size and Forecast, By End User
- 6.6. Market Size and Forecast, By Distribution Channel
- 6.7. Market Size and Forecast, By Technology
- 6.8. United States Inhalation Devices Market Outlook
- 6.8.1. Market Size by Value
- 6.8.2. Market Size and Forecast By Product Type
- 6.8.3. Market Size and Forecast By Therapeutic Application
- 6.9. Canada Inhalation Devices Market Outlook
- 6.9.1. Market Size by Value
- 6.9.2. Market Size and Forecast By Product Type
- 6.9.3. Market Size and Forecast By Therapeutic Application
- 6.10. Mexico Inhalation Devices Market Outlook
- 6.10.1. Market Size by Value
- 6.10.2. Market Size and Forecast By Product Type
- 6.10.3. Market Size and Forecast By Therapeutic Application
- 7. Competitive Landscape
- 7.1. Competitive Dashboard
- 7.2. Business Strategies Adopted by Key Players
- 7.3. Porter's Five Forces
- 7.4. Company Profile
- 7.4.1. GSK plc
- 7.4.1.1. Company Snapshot
- 7.4.1.2. Company Overview
- 7.4.1.3. Financial Highlights
- 7.4.1.4. Geographic Insights
- 7.4.1.5. Business Segment & Performance
- 7.4.1.6. Product Portfolio
- 7.4.1.7. Key Executives
- 7.4.1.8. Strategic Moves & Developments
- 7.4.2. AstraZeneca
- 7.4.3. Novartis AG
- 7.4.4. Teva Respiratory LLC
- 7.4.5. Boehringer Ingelheim International GmbH
- 7.4.6. Cipla LTD
- 7.4.7. Lupin Ltd
- 7.4.8. Viatris Inc.
- 7.4.9. CHIESI Farmaceutici S.p.A.
- 7.4.10. OMRON Corporation
- 7.4.11. Koninklijke Philips N.V.
- 7.4.12. PARI GmbH
- 8. Strategic Recommendations
- 9. Annexure
- 9.1. FAQ`s
- 9.2. Notes
- 10. Disclaimer
Table 2: Top 10 Counties Economic Snapshot 2024
Table 3: Economic Snapshot of Other Prominent Countries 2022
Table 4: Average Exchange Rates for Converting Foreign Currencies into U.S. Dollars
Table 5: North America Inhalation Devices Market Size and Forecast, By Product Type (2020 to 2031F) (In USD Billion)
Table 6: North America Inhalation Devices Market Size and Forecast, By Therapeutic Application (2020 to 2031F) (In USD Billion)
Table 7: North America Inhalation Devices Market Size and Forecast, By End User (2020 to 2031F) (In USD Billion)
Table 8: North America Inhalation Devices Market Size and Forecast, By Distribution Channel (2020 to 2031F) (In USD Billion)
Table 9: North America Inhalation Devices Market Size and Forecast, By Technology (2020 to 2031F) (In USD Billion)
Table 10: United States Inhalation Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 11: United States Inhalation Devices Market Size and Forecast By Therapeutic Application (2020 to 2031F) (In USD Billion)
Table 12: Canada Inhalation Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 13: Canada Inhalation Devices Market Size and Forecast By Therapeutic Application (2020 to 2031F) (In USD Billion)
Table 14: Mexico Inhalation Devices Market Size and Forecast By Product Type (2020 to 2031F) (In USD Billion)
Table 15: Mexico Inhalation Devices Market Size and Forecast By Therapeutic Application (2020 to 2031F) (In USD Billion)
Table 16: Competitive Dashboard of top 5 players, 2025
Figure 2: North America Inhalation Devices Market Share By Country (2025)
Figure 3: United States Inhalation Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 4: Canada Inhalation Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 5: Mexico Inhalation Devices Market Size By Value (2020, 2025 & 2031F) (in USD Billion)
Figure 6: Porter's Five Forces of Global Inhalation Devices Market
Inhalation Devices Market Research FAQs
Related Reports
One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information
One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information
Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information
All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information
Safe and Secure SSL Encrypted
Quick Contacts
Want to customize this report?
We offer 10% Free Customization at the time of purchase
Get Free Customization
Our Clients
Budget constraints? Get in touch with us for special pricing
Request DiscountOrder Detail
- Order Placed (13 October, 2026)
- Notify To Team (13 October, 2026)
- Report updation (14 October, 2026)
- Report Quality Check (14 October, 2026)
- Report Dispatch (15 October, 2026)
- Hard Copy
Recently Viewed Products
North America Inhalation Devices Market Outlook, 2031
We are friendly and approachable, give us a call.